Yan Nerng Lye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yan Nerng Lye has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Carolyn Shan-Yeu Tien
Department of Renal Medicine, Singapore General Hospital, Singapore
1 shared publication - Chin Yee Lee
Department of Renal Medicine Singapore General Hospital Singapore Singapore
1 shared publication - Haoyang Chen
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
1 shared publication - Ian Tatt Liew
Department of Renal Medicine, Singapore General Hospital, Singapore, Singapore
1 shared publication - Jia Qin Tan
Department of Renal Medicine Singapore General Hospital Singapore Singapore
1 shared publication - Khung Keong Yeo
National Heart Center Singapore, Singapore, Singapore
1 shared publication
Latest Publications
- Open Access
- 23 October 2025
- Published by Wiley in Nephrology
- Vol. 30 (10) , e70141
Burden of Valvular Heart Disease Diagnosed on Protocolised Echocardiography for Waitlist Placement in End‐Stage Kidney Patients
Aim: The burden of valvular heart disease (VHD), which is high amongst end‐stage kidney disease patients (ESKD), is less well defined in those referred to the transplant waitlist. We aimed to determine the prevalence, incidence, impact on survival and risk factors of VHD in ESKD patients who are referred for deceased donor kidney transplant (DDKT). Methods: This is a single‐centre retrospective cohort analysis of ESKD patients who were referred for waitlist placement between 2009 and 2017 and underwent at least 1 transthoracic echocardiogram (TTE), then followed up until death or transplantation. Significant VHD was defined as VHD that was moderate or worse in severity as assessed on echocardiography. Results: Of the 512 patients included, 89 (17.4%) had significant baseline VHD. Over a median follow‐up of 6.6 years, severe VHD (adjusted HR (aHR) 2.73, 95% CI 1.28–5.83, p = 0.009), severe tricuspid regurgitation (aHR 3.04, 95% CI 1.20–7.69, p = 0.02), significant aortic stenosis (aHR 2.93, 95% CI 1.15–7.45, p = 0.02), MS (aHR 3.83, 95% CI 1.54–9.50, p = 0.004) and AR (aHR 1.76, 95% CI 1.05–2.97, p = 0.03) were independently associated with all‐cause mortality. In 350 patients with repeat TTEs, 53 (15.1%) developed de novo significant VHD or progression of pre‐existing VHD, which was independently associated with all‐cause mortality (aHR 2.02, 95% CI 1.14–3.61, p = 0.02). Age, time on dialysis, and mineral bone disease were associated with baseline VHD and de novo or progression of pre‐existing VHD. Conclusion: VHD is common amongst ESKD patients referred for DDKT waitlist. Both baseline and progressive VHD predict worse survival.
- 23 October 2025
- Published by Wiley in Nephrology
- Vol. 30 (10) , e70141
Open AccessBurden of Valvular Heart Disease Diagnosed on Protocolised Echocardiography for Waitlist Placement in End‐Stage Kidney Patients
Aim: The burden of valvular heart disease (VHD), which is high amongst end‐stage kidney disease patients (ESKD), is less well defined in those referred to the transplant waitlist. We aimed to determine the prevalence, incidence, impact on survival and risk factors of VHD in ESKD patients who are referred for deceased donor kidney transplant (DDKT). Methods: This is a single‐centre retrospective cohort analysis of ESKD patients who were referred for waitlist placement between 2009 and 2017 and underwent at least 1 transthoracic echocardiogram (TTE), then followed up until death or transplantation. Significant VHD was defined as VHD that was moderate or worse in severity as assessed on echocardiography. Results: Of the 512 patients included, 89 (17.4%) had significant baseline VHD. Over a median follow‐up of 6.6 years, severe VHD (adjusted HR (aHR) 2.73, 95% CI 1.28–5.83, p = 0.009), severe tricuspid regurgitation (aHR 3.04, 95% CI 1.20–7.69, p = 0.02), significant aortic stenosis (aHR 2.93, 95% CI 1.15–7.45, p = 0.02), MS (aHR 3.83, 95% CI 1.54–9.50, p = 0.004) and AR (aHR 1.76, 95% CI 1.05–2.97, p = 0.03) were independently associated with all‐cause mortality. In 350 patients with repeat TTEs, 53 (15.1%) developed de novo significant VHD or progression of pre‐existing VHD, which was independently associated with all‐cause mortality (aHR 2.02, 95% CI 1.14–3.61, p = 0.02). Age, time on dialysis, and mineral bone disease were associated with baseline VHD and de novo or progression of pre‐existing VHD. Conclusion: VHD is common amongst ESKD patients referred for DDKT waitlist. Both baseline and progressive VHD predict worse survival.